No CrossRef data available.
Article contents
Highly Penetrant Genetic Disorders: An Atlas for Critical Illness Insurance
Published online by Cambridge University Press: 10 June 2011
Abstract
For estimates of critical illness (CI) insurance premiums in the presence of a known mutation leading to a genetic disorder, the key quantity is the penetrance, that is the probability q(x) that the disease has developed by age x. This function is often estimated in the genetics literature, though typically with large confidence intervals. In this paper we suggest that the main features of real penetrance functions can be represented reasonably well by simple one-parameter families of functions, which can be scaled to fit the age range and lifetime penetrance. This gives a simple, direct, pragmatic way to obtain quick estimates of CI premium rates from published penetrance estimates, and also some indicative bounds for such premium rates, which are useful since confidence intervals usually cannot be estimated. To aid this process, as a short-cut to the solution of Thiele's equations in a multiple-state model, we give extensive tables in another report (Macdonald & Yang, 2003).
- Type
- Sessional meetings: papers and abstracts of discussions
- Information
- Copyright
- Copyright © Institute and Faculty of Actuaries 2003
References
Churchill, D., Bear, J., Morgan, J., Payne, R., McManamon, P. & Gault, H. (1984). Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney International, 26, 190–193.CrossRefGoogle ScholarPubMed
Daykin, C.D., Akers, D.A., Macdonald, A.S., McGleenan, T., Paul, D. & Turvey, P.J. (2003). Genetics and insurance — some social policy issues. British Actuarial Journal, 9, 787–874.CrossRefGoogle Scholar
Dinani, A., Grimshaw, D., Robjohns, N., Somerville, A.S., Spry, A. & Stafforth, J. (2000). A critical review: report of the critical illness healthcare study group. Presented to the Staple Inn Actuarial Society.Google Scholar
Ford, D., Easton, D.F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D.T., Weber, B., Lenoir, G., Chang-Claude, J., Sobol, H., Teare, M.D., Struewing, J., Arason, A., Scherneck, S., Peto, J., Rebbeck, T.R., Tonin, P., Neuhausen, S., Barkardottir, R., Eyfjord, J., Lynch, H., Ponder, B.A.J., Gayther, S.A., Birch, J.M., Lindblom, A., Stoppa-Lyonnet, D., Bignon, Y., Borg, A., Hamann, U., Haites, N., Scott, R.J., Maugard, C.M., Vasen, H., Seitz, S., Cannon-Albright, L.A., Schofield, A., Zelada-Hedman, M. & the Breast Cancer Linkage Consortium (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. American Journal of Human Genetics, 62, 676–689.CrossRefGoogle ScholarPubMed
Gui, E.H. & Macdonald, A.S. (2002). A Nelson-Aalen estimate of the incidence rates of early-onset Alzheimer's disease associated with the Presenilin-1 gene. ASTIN Bulletin, 32, 1–42.CrossRefGoogle Scholar
Gutierrez, M.C. & Macdonald, A.S. (2003). Adult polycystic kidney disease and critical illness insurance. North American Actuarial Journal, 7:2, 93–115.CrossRefGoogle Scholar
Hodge, S.E. (2002), Ascertainment. In Bio statistical genetics and genetic epidemiology. Ed. Elston, R., Olson, J. & Palmer, L., John Wiley.Google Scholar
Hoem, J.M. (1988). The versatility of the Markov chain as a tool in the mathematics of life insurance. Transactions of the 23rd International Congress of Actuaries, Helsinki S, 171–202.Google Scholar
Macdonald, A.S. (2003). Genetics and insurance: what have we learned so far? Scandinavian Actuarial Journal, 2003, 324–348.CrossRefGoogle Scholar
Macdonald, A.S., Waters, H.R. & Wekwete, C.T. (2003a). The genetics of breast and ovarian cancer. I: a model of family history. Scandinavian Actuarial Journal, 2003, 1–27.CrossRefGoogle Scholar
Macdonald, A.S., Waters, H.R. & Wekwete, C.T. (2003b). The genetics of breast and ovarian cancer. II: a model of critical illness insurance. Scandinavian Actuarial Journal, 2003, 28–50.CrossRefGoogle Scholar
Macdonald, A.S. & Yang, S.Y. (2003). Tables of representative premiums for critical illness insurance policies in the presence of model genetic disorders. Occasional actuarial research document No. 42, Faculty and Institute of Actuaries.Google Scholar
Roos, R.A.C., der Vlis, M.V., Hermans, J., Elshove, H.M., Moll, A.C., van de Kamp, J.J.P. & Bruyn, G.W. (1991). Age at onset in Huntington's disease: effect of line of inheritance and patient's sex. Journal of Medical Genetics, 28, 515–519.CrossRefGoogle ScholarPubMed
Smith, C. (1998). Huntingtons chorea — a mathematical model for life insurance. Swiss Reinsurance Company, Zurich.Google Scholar
United States Renal Diseases System (1999). Annual report of the United States Renal Diseases System. USRDS.Google Scholar
Wendt, G.G. & Drohm, C. (1972). Die Huntingtonsche chorea. Eine populations gentische studie. Advances in Human Genetics, IV, 1–121.Google Scholar
Wilkie, A.D. (2000). Report by the Independent Actuary on the application by the Association of British Insurers to the Genetics and Insurance Committee for approval to use genetic test results for insurance risk assessment — use of Huntington's disease test in life insurance. Report available by request to the Genetics and Insurance Committee.Google Scholar